Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Deal Watch

This page shows the latest Deal Watch news and features for those working in and with pharma, biotech and healthcare.

The M&A trend in pharma

The M&A trend in pharma

The lion's share of deal-making in 2014 continued to revolve around Western markets. ... Read more about pharma's M&A activity in the latest Deal Watch article.

Latest news

  • The hunted now hunt: biotechs become buyers The hunted now hunt: biotechs become buyers

    Biotech deals feature in our latest Deal Watch article.

  • Biologics buoyant

    This continues the biologics trend noted in previous Deal Watch reviews. ... One deal of note during this period was the entry of Bayer Healthcare's dermatology business, Intendis, into the aesthetic dermatology area.

  • Orphan drug focus

    During this period, GSK closed its deal with Nabi for NicVax, a nicotine addiction vaccine in phase III (this was announced in the Deal Watch article on page 15 of the ... P2. 960. Cellzome/GSK. inflammatory disease. Platform. 690. Ariad/Merck.

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    When writing this bimonthly edition of Medius’s Deal Watch I have been struck by how often the words 'it’s unusual.' have appeared. ... Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for.

  • Deal Watch January 2018

    Three companies have been particularly active in deal making this month: Sanofi, Celgene and Takeda - more on this below. ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal Watch over the last few months but focused more

  • Pharma deals continue to slide Pharma deals continue to slide

    Deal Watch investigates. There is plenty of evidence that the number and value of biopharma M&A and licensing deals in 2016 and 2017 is declining. ... This month Deal Watch reviews the potential impact of some of the macroeconomic factors and the impact

  • Deal Watch - May 2017 Deal Watch - May 2017

    So although the due diligence had identified the issues Abbott had chosen to sign the deal. ... In both cases the upfront is around 44% of the total deal value.

  • Deal Watch March 2017 Deal Watch March 2017

    Each month the Deal Watch team ploughs our merry way through the details of 600 plus deals to bring you the edited highlights. ... X-Chem does it again. Twice. In Japanese. X-Chem is a name that comes up with great regularity in the Deal Watch database.

More from intelligence
Approximately 78 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......

Quick links